A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019-present) [0.03%]
2019年至今的针对刺突血管紧张素转换酶2相互作用的抗冠状病毒药物专利综述
Xing Huang,Heng Gao,Jiwei Zhang et al.
Xing Huang et al.
Introduction: The Angiotensin-converting enzyme 2 (ACE2) receptor, crucial for coronavirus recognition of host cells, is a key target for therapeutic intervention against SARS-CoV-2 and related coronaviruses. Therefore, t...
Keting Bao,Peiran Li,Dingding Gao
Keting Bao
Introduction: Signal transducer and activator of transcription 3 (STAT3), a member of the STAT protein family, serves as both a signal transducer and a transcription factor. Previous studies have highlighted its pivotal r...
Chiara Spaggiari,Clementine Yamukujije,Marco Pieroni et al.
Chiara Spaggiari et al.
Introduction: The collective behavior of bacteria is regulated by Quorum Sensing (QS), in which bacteria release chemical signals and express virulence genes in a cell density-dependent manner. Quorum Sensing inhibitors (...
Elia Ravegnini,Andrea Trabocchi,Elena Lenci
Elia Ravegnini
Introduction: Targeting three-dimensional RNA structures with traditional drug - like small molecules is gaining wide attention in both the academia and the pharmaceutical industries, due to their good oral bioavailabilit...
Matjaz Brvar,Thomas J O&#x;Neill,Oliver Plettenburg et al.
Matjaz Brvar et al.
Introduction: MALT1 paracaspase acts as a molecular scaffold and a proteolytic enzyme in immune cells. MALT1 has emerged as a promising drug target for cancer therapy, and especially for targeting MALT1 in aggressive lymp...
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014-present) [0.03%]
肽精氨酸脱亚氨酶4(PAD4)抑制剂的专利综述(2014年-至今)
Sheenagh Grace Aiken,Thomas Grimes,Shonagh Munro et al.
Sheenagh Grace Aiken et al.
Introduction: PAD4 mediates the post-translational modification of arginine residues into citrulline which can have profound effects on protein structure, function and interactions. Protein citrullination and neutrophil e...
An updated patent review of antitumor macrocyclic kinase inhibitors (2019 present) [0.03%]
抗肿瘤巨环激酶抑制剂的专利综述更新（2019年至今）
Xintao He,Lu Chen,Shuangshuang Wu et al.
Xintao He et al.
Introduction: Small molecule kinase inhibitors are crucial in the treatment of tumors, and the development of novel inhibitors is a primary approach to combat the continuous emergence of drug resistance. Macrocyclization ...
Thanigaimalai Pillaiyar,Stefan Laufer
Thanigaimalai Pillaiyar
Introduction: Atypical chemokine receptor 3 (ACKR3) (formerly CXCR7) regulates various biological processes through its ligands and is closely associated with numerous diseases, including inflammation, cancer, cardiovascu...
Guoquan Wan,Siyan Li,Qifan Tang et al.
Guoquan Wan et al.
Introduction: EZH2 forms the PRC2 complex with SUZ12 and EED. As a crucial catalytic subunit of PRC2, EZH2 modifies histone H3K27 via its SET domain, resulting in chromatin condensation and suppressing the transcription o...
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities [0.03%]
RORγt抑制剂在自身免疫性疾病治疗中的临床开发：挑战与机遇
Nannan Sun,Yonghui Wang
Nannan Sun
Introduction: Nuclear receptor retinoid-related orphan receptor gamma-t (RORγt) is a major transcription factor for Th17 cell differentiation and IL-17 production. RORγt has been considered as a promising drug target fo...